Home  /  News  /  McAndrews News

McAndrews Shareholder Herbert D. Hart III to Discuss PTAB Trial Proceedings under the AIA at 2013 IPO Annual Meeting

Date: August 22, 2013 || McAndrews News

McAndrews, Held & Malloy Shareholder Herbert D. Hart III will be a featured speaker at the Intellectual Property Owners Association’s (IPO) 2013 Annual Meeting.  Because of his significant experience litigating before the Patent Trial and Appeal Board (PTAB), Hart was invited to organize and participate in the session titled, “Back To The Future: Trial Practice at the PTAB,” on September 16, 2013, from 1:45-3:15 pm. 

Specifically, Hart will address current practice, decisions, and strategies in both litigating and managing PTAB trials, which are highly specialized, fast-paced, and unforgiving for those inexperienced in PTAB trial practice. Hart will also provide trial practice tips directly applicable to today’s post-grant trial proceedings. Other long-time PTAB practitioners featured on the panel include:

  • Bruce Stoner, Greenblum & Bernstein, P.L.C. (Former Chief Administrative Patent Judge, Board of Patent Appeals and Interferences), Moderator
  • Oliver Ashe, Ashe, P.C., Speaker
  • Mark A. Charles, The Procter & Gamble Company, Speaker
  • Danny Huntington, Rothwell, Figg, Ernst & Manbeck, P.C., Speaker
For more information and to register, click here.

Herbert D. Hart III has significant experience in litigation before the PTAB, specifically in life science and chemical technologies. He is a frequent speaker on PTAB trial practice and he has served as an expert witness on interference practice. Hart serves on the AIPLA Special Task Force on AIA Rulemaking and he was also appointed to the six-member IPO/ABA/AIPLA Expert Committee on Regulations for Conducting New PGR/IPR Procedures (the “Gang of 6”). He is widely published in the field of intellectual property law and has provided commentary in numerous legal, business and scientific publications.  Recently, Hart has spoken before clients, associations, and other audiences regarding rulemaking under the post-grant provisions of the AIA. He also is an associate editor and contributing author of the ABA book, ANDA Litigation: Strategies and Tactics for Pharmaceutical Patent Litigators.